NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
12 trialsNCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT04319757 2024-12-05
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase 1 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03287674 2023-03-01
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Completed
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02096614 2021-06-18
Investigator Initiated Phase 1 Study of TBI-1201
Mie University
Phase 1 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01105650 2017-12-28
MT2009-30
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02118285 2017-12-05
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02482090 2017-08-16
TIL Therapy for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1 Completed